Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pipecuronium→

Pipecuronium Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
68399-58-6
Molecular formula
C35H62N4O4+2
Molecular weight
602.9 g/mol
Drug class
Long-acting non-depolarising neuromuscular blocking agentsteroidal nicotinic acetylcholine-receptor antagonist
Mechanism of action
Competitively antagonises nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine-mediated depolarisation and producing skeletal-muscle relaxation.
Indications / reported uses
  • Adjunct to general anaesthesia to provide skeletal-muscle relaxation during surgical procedures and to facilitate controlled ventilation, where the product is authorised.

Sources: https://www.ncbi.nlm.nih.gov/mesh/68017300 · https://meshb.nlm.nih.gov/record/ui?ui=D017300

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Long-acting non-depolarising neuromuscular blocking agent; steroidal nicotinic acetylcholine-receptor antagonist

Mechanism of action

Competitively antagonises nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine-mediated depolarisation and producing skeletal-muscle relaxation.

General use cases

  • Adjunct to general anaesthesia to provide skeletal-muscle relaxation during surgical procedures and to facilitate controlled ventilation, where the product is authorised.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Pipecuronium Environmental Risk Assessment (ERA) (the Pipecuronium ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.